HOOKIPA PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-07-22: Reporting owner Cassidy Sean A; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-06-17: Reporting owner Peters Malte; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-06-17: Reporting owner van de Winkel Jan; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-06-17: Reporting owner Kaufman David Ross; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-07-22 | Cassidy Sean A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,800 9,800 owned after | $6.44 exercise price | 2024-07-24 | |
| 2024-06-17 | Peters Malte Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,000 49,000 owned after | $0.71 exercise price | 2024-06-18 | |
| 2024-06-17 | van de Winkel Jan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +98,000 98,000 owned after | $0.71 exercise price | 2024-06-18 | |
| 2024-06-17 | Kaufman David Ross Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,000 49,000 owned after | $0.71 exercise price | 2024-06-18 | |
| 2024-06-17 | O'Neill Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,000 49,000 owned after | $0.71 exercise price | 2024-06-18 | |
| 2024-06-17 | Coelho Mary Theresa Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,000 49,000 owned after | $0.71 exercise price | 2024-06-18 | |
| 2024-06-17 | Reilly Timothy P. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,000 49,000 owned after | $0.71 exercise price | 2024-06-18 | |
| 2024-04-15 | Orlinger Klaus Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +367,300 367,300 owned after | $0.76 exercise price | 2024-04-17 | |
| 2024-04-15 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +971,400 971,400 owned after | $0.76 exercise price | 2024-04-17 | |
| 2024-04-15 | Winderlich Mark Officer (Chief Development Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $0.76 exercise price | 2024-04-17 | |
| 2024-04-15 | Winderlich Mark Officer (Chief Development Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.76 exercise price | 2024-04-17 | |
| 2024-04-15 | Kandera Reinhard Director, Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +406,200 406,200 owned after | $0.76 exercise price | 2024-04-17 | |
| 2024-04-15 | Necina Roman Officer (Chief Operations Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +367,300 367,300 owned after | $0.76 exercise price | 2024-04-17 |